(Q38240748)

31 August 2017

HDL and cardiovascular disease. (English)

1 reference

31 August 2017

cardiovascular disease

1 reference

2

G Kees Hovingh

0 references

author name string

Daniel J Rader

series ordinal

1

1 reference

PubMed ID

25131981

31 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

384

1 reference

31 August 2017

9943

1 reference

31 August 2017

618-625

1 reference

RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein metabolism, composition, function, and deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Hepatic ABC transporters and triglyceride metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Cubilin and megalin: partners in lipoprotein and vitamin metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoproteins: a consensus statement from the National Lipid Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein subclasses and their relationship to cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Approach to the patient with extremely low HDL-cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Inherited disorders of HDL metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Mendelian disorders of high-density lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

HDL deficiency and atherosclerosis: lessons from Tangier disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Marked HDL deficiency and premature coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Compromised LCAT function is associated with increased atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

A review of CETP and its relation to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Common variants associated with plasma triglycerides and risk for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Aldosterone, sodium, and hypertension: lessons from torcetrapib?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Future of cholesteryl ester transfer protein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Novel therapies focused on the high-density lipoprotein particle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

ATP-binding cassette transporters, atherosclerosis, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

An abundant dysfunctional apolipoprotein A1 in human atheroma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Novel HDL-directed pharmacotherapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961217-4

7 January 2021

10.1016/S0140-6736(14)61217-4

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25131981